Yuhan Corp stock (KR7000100008): R&D Day spin-off plans and valuation metrics under the spotlight

Yuhan shares in South Korea trade in focus after the company used its May 28 R&D Day to outline a spin-off of its allergy drug candidate into a NewCo as part of a post-Lazertinib strategy, putting renewed attention on the group’s pipeline and current valuation multiples.

Yuhan shares on the Korea Exchange are drawing attention at the end of the week after the South Korean pharmaceutical group used its R&D Day on 05/28/2026 to detail a plan to spin off its allergy treatment candidate into a separate NewCo as part of a broader "post-Lazertinib" strategy, according to company comments cited in local coverage of the event.

At the event, management described the NewCo as a central pillar of its strategy once royalties from Lazertinib, marketed as Lazecra in South Korea, begin to mature, positioning the allergy pipeline asset YH35324 as the core of the proposed entity, according to a report summarizing the R&D Day presentations on 05/28/2026.

The R&D Day in Seoul underlined how the company, one of South Korea’s established pharmaceutical names, aims to transition beyond its current flagship oncology asset by highlighting five key pipeline candidates, including the allergy therapy YH35324 and the MASH (metabolic dysfunction-associated steatohepatitis) candidate YH25724, as reported in a 05/28/2026 article on Yuhan’s pipeline strategy.

The stock trades on the Korea Exchange under the ticker 000100, and investors in South Korea are now assessing how the contemplated NewCo structure might unlock value from YH35324 while leaving Lazertinib-related economics and other late-stage projects with the parent, based on the roadmap management sketched at the R&D Day on 05/28/2026.

According to recent Korea Exchange data, the shares continue to change hands in Korean won on the KRX main board, with liquidity reflecting the company’s role as a well-followed domestic pharmaceutical name, while no official timetable or valuation has yet been announced for the proposed NewCo transaction as of 05/29/2026.

For investors in Germany, the stock is also accessible via secondary trading lines such as Tradegate, where the shares can be dealt in euros in parallel with the primary South Korean listing, offering a bridge for European retail investors who follow developments in the South Korean healthcare sector.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Yuhan
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Seoul, South Korea
• Core markets: South Korea with growing exposure to global pharmaceutical markets through licensing and partnerships
• Key revenue drivers: Prescription drugs including Lazertinib, over-the-counter products, and partnered therapies, complemented by a pipeline of allergy and liver-disease candidates
• Home exchange/listing venue: Korea Exchange (000100)
• Trading currency: KRW

Yuhan Corp: core business model

Yuhan generates most of its income by researching, developing, manufacturing, and distributing branded and partnered medicines, with oncology, allergy, liver disease and everyday healthcare products acting as the main sources of revenue growth.

Recent corporate actions

During its R&D Day on 05/28/2026 in Seoul, the company outlined a structural move to establish a NewCo built around its allergy treatment candidate YH35324, which it framed as a cornerstone of its strategy for the period after Lazertinib, alongside a group of other key pipeline assets that are being advanced through clinical development.

Valuation metrics and multiples for Yuhan Corp

With the market digesting the R&D Day disclosures, attention has also turned to how the stock is valued versus its earnings and cash flow profile in South Korea’s pharmaceutical sector, where investors often compare price-to-earnings and enterprise-value-to-EBITDA multiples across peer companies.

Public data from financial information providers covering the Korea Exchange indicate that Yuhan’s shares are typically assessed on a combination of trailing and forward P/E ratios adjusted for the contribution from Lazertinib royalties, while analysts and investors also reference enterprise-value-based multiples to factor in the value of the pipeline and the potential impact of actions such as the proposed NewCo spin-off.

Conclusion

The company’s late-May R&D Day in South Korea has shifted attention toward a potential NewCo for its allergy pipeline and clarified how management is planning for the period after Lazertinib’s peak contribution.

At the same time, the stock’s valuation metrics are being revisited as investors weigh the risk-reward balance between existing cash-generating assets and earlier-stage candidates such as YH35324 and YH25724, as well as the possible impact of the proposed spin-off structure on shareholder value over time.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.